Head-to-head evidence
HS-20118 vs icotrokinra
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-23 receptor · full Psoriasis pipeline
HS-20118
Developed by Avere Therapeutics under a licence from Hansoh Pharmaceutical Group
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2026 · NCT06846710 (registry estimate)
icotrokinra
Marketed by Johnson & Johnson and partners
NCT05223868 · Phase 2 · completed
The trial randomized 255 participants to five blinded icotrokinra dose groups or placebo, with approximately 41–43 participants per group. Its primary clinical psoriasis endpoint, PASI-75 at Week 16, was statistically significantly better for every icotrokinra dose than placebo.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HS-20118's landscape · icotrokinra's landscape